Published in Expert Rev Anti Infect Ther on February 01, 2006
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol (2012) 0.98
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses (2012) 0.87
A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J (2010) 0.86
Interactions of human complement with virus particles containing the Nipah virus glycoproteins. J Virol (2011) 0.82
A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b. J Virol (2014) 0.76
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science (2012) 2.29
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis (2007) 1.68
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem (2002) 1.54
Antibodies to Nipah or Nipah-like viruses in bats, China. Emerg Infect Dis (2008) 1.53
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A (2007) 1.50
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine (2008) 1.41
Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding. J Virol (2008) 1.40
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 1.39
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J (2007) 1.30
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol J (2005) 1.21
Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. Virology (2007) 1.21
A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol (2010) 1.21
A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med (2012) 1.20
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods (2006) 1.19
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol (2010) 1.17
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis (2014) 1.16
Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A (2010) 1.14
Animal challenge models of henipavirus infection and pathogenesis. Curr Top Microbiol Immunol (2012) 1.11
Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol (2009) 1.09
Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol Cell Biol (2005) 1.06
The YPLGVG sequence of the Nipah virus matrix protein is required for budding. Virol J (2008) 1.05
Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection. J Virol (2008) 1.05
Antibodies to henipavirus or henipa-like viruses in domestic pigs in Ghana, West Africa. PLoS One (2011) 1.02
Hendra and Nipah viruses: pathogenesis and therapeutics. Curr Mol Med (2005) 1.02
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol (2004) 0.99
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Henipavirus neutralising antibodies in an isolated island population of African fruit bats. PLoS One (2012) 0.98
Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins. J Virol (2012) 0.96
Human metapneumovirus reinfection among children in Thailand determined by ELISA using purified soluble fusion protein. J Infect Dis (2008) 0.92
Host cell tropism mediated by Australian bat lyssavirus envelope glycoproteins. Virology (2013) 0.92
The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages. Virus Res (2006) 0.91
Use of cross-reactive serological assays for detecting novel pathogens in wildlife: assessing an appropriate cutoff for henipavirus assays in African bats. J Virol Methods (2013) 0.90
Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. Viruses (2010) 0.90
Recombinant Hendra viruses expressing a reporter gene retain pathogenicity in ferrets. Virol J (2013) 0.89
New insights into the Hendra virus attachment and entry process from structures of the virus G glycoprotein and its complex with Ephrin-B2. PLoS One (2012) 0.89
Paramyxovirus entry. Adv Exp Med Biol (2013) 0.88
Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus. Glycobiology (2011) 0.88
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses (2012) 0.87
A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J Virol Methods (2009) 0.87
Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J (2013) 0.86
A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J (2010) 0.86
Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert Rev Anti Infect Ther (2006) 0.85
Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection. Retrovirology (2012) 0.84
Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol (2003) 0.84
Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virol Sin (2013) 0.84
Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry (2002) 0.83
Probing the HIV gp120 envelope glycoprotein conformation by NMR. J Biol Chem (2011) 0.83
Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog (2013) 0.83
Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery. Methods Mol Biol (2009) 0.82
Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine (2010) 0.81
A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol (2014) 0.81
Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin Cell Dev Biol (2011) 0.81
Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase. J Virol Methods (2011) 0.81
Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Vaccine (2003) 0.80
Mutations in the G-H loop region of ephrin-B2 can enhance Nipah virus binding and infection. J Gen Virol (2011) 0.78
Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins. PLoS One (2013) 0.77
Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infection. Virol J (2009) 0.77
Antigen capture ELISA system for henipaviruses using polyclonal antibodies obtained by DNA immunization. Arch Virol (2012) 0.76
Pillars article: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996. 272: 872-877. J Immunol (2011) 0.75
Antibody fragment expression and purification. Methods Mol Biol (2009) 0.75
Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers. Emerg Infect Dis (2022) 0.75
Novel Hendra Virus Variant Detected by Sentinel Surveillance of Horses in Australia. Emerg Infect Dis (2022) 0.75